Bristol Myers Squibb consensus stays cautious, shares trade near recent lows

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 15:39.

Bristol Myers Squibb (US1101221083) sits in the large-cap U.S. pharma cohort, with its BMY ticker listed on the NYSE in the S&P 500 index. The Tuesday focus is the analyst consensus and how Wall Street currently values the shares relative to the healthcare peer group.

What analysts are pricing in

Analyst estimates for Bristol Myers Squibb cluster above the present market level, reflecting a cautious upside view rather than aggressive growth expectations. One recent aggregation puts the average 12-month target near 63 dollars per share, compared with a spot price around the mid-50s, implying a moderate potential gap.

Rating distributions from major houses typically lean toward Hold or equivalent, with fewer outright Buy calls than for faster-growing biotech names, underscoring the mixed sentiment on BMY. This pattern positions Bristol Myers Squibb as a value and cash-flow story rather than a momentum stock, in contrast with peers such as Merck or Eli Lilly, which carry more pronounced growth narratives.

How the shares trade today

In recent U.S. trading sessions on the NYSE, Bristol Myers Squibb shares changed hands in the mid-50 dollar range, with a latest reference around 54.70 dollars and intraday volatility constrained to roughly one dollar. Trading volume on June 22 ran close to 16 million shares, showing robust liquidity for institutional and retail investors.

The shares remain below many published target levels, a sign that the Street sees some room for rerating if execution on the pipeline and cost discipline delivers according to expectations. Against the wider healthcare sector, BMY trades at a discount to some peers on forward earnings multiples, which mirrors the more muted growth outlook reflected in consensus reports.

The products behind the stock

Bristol Myers Squibb generates revenue primarily from branded prescription medicines in oncology, hematology, immunology and cardiovascular disease, including key franchises such as Opdivo and Eliquis. The company invests heavily in late-stage clinical programs to sustain its portfolio as older blockbusters face patent expiry, a central element of the BMY equity story for long-term holders.

Where the stock trades now

The Bristol Myers Squibb shares (US1101221083) recently traded on the NYSE at about 54.70 US dollars per share, based on the June 22 closing data. This places the company’s equity value below the average analyst target quoted in current consensus compilations.

Disclaimer: This text is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. All data are based on sources cited and may change without notice.